The pharmacotherapy for pit viper envenoming in the United States: A brief retrospective on roots, recurrence, and risk

References

• Bush S, Ruha AM, Seifert SA, Morgan DL, Lewis BJ, Arnold TC, et al. Comparison of F(ab’)2 versus Fab antivenom for pit viper envenomation: a prospective, blinded, multicentre, randomized clinical trial. Clin Toxicol (Phila) 2014; 31:1–9.
   Google Scholar
• Schroeder HW, Wald D, Greenspan NS. Immunoglobulins: structure and function. In: Paul W, ed. Fundamental Immunology. Philadelphia: Lippincott, Williams and Wilkins, 2012:1312; 129–149.
   Google Scholar
• León G, Monge M, Rojas E, Lomonte B, Gutiérrez JM. Comparison between IgG and F(ab’)2 polyvalent antivenoms: neutralization of systemic effects induced by Bothrops asper venom in mice, extravasation to muscle tissue, and potential for induction of adverse events. Toxicon 2001; 39:793–801.
   PubMed Web of Science ®Google Scholar
• Minton SA. Common antigens in snake venom. In: Lee CY, ed. Snake Venoms, Handbook of Experimental Pharmacology. Part IV. Berlin: Springer Verlag; 1979:847–862.
   Google Scholar
• Githens TS, Wolff NOC. The polyvalency of crotalidic antivenins. J Immunol 1939; 37:33–49.
   Google Scholar
• Gold BS, Dart RC, Barish RA. Bites of venomous snakes. N Engl J Med 2002; 347:347–356.
   PubMed Web of Science ®Google Scholar
• Seifert SA, Boyer LV, Benson BE, Rogers JL. AAPCC database characterization of native U.S. venomous snake exposures, 2001–2005. Clin Toxicol (Phila) 2009; 47:327–335.
   PubMed Web of Science ®Google Scholar
• Langley R, Mack K, Haileyesus T, Proescholdbell S, Annest JL. National estimates of noncanine bite and sting injuries treated in US hospital emergency depratments, 2001–2010. Wilderness Environ Med 2014; 25:14–23.
   PubMed Web of Science ®Google Scholar
• Weinstein SA, Dart RC, Staples A, White J. Envenomations: an overview of clinical toxinology for the primary care physician. Amer Fam Physician 2009; 80:793–802.
   PubMed Web of Science ®Google Scholar
• Jurkovitch GJ, Luterman A, McCullar K, Ramenofsky ML, Curreri PW. Complications of Crotalidae antivenin therapy. J Trauma 1988; 28:1032–1037.
   PubMed Web of Science ®Google Scholar
• White RR, Weber RA. Poisonous snakebite in central Texas. Possible indicators for antivenin treatment. Ann Surg 1991; 213:466–471 (and discussion, 471–472).
   PubMed Web of Science ®Google Scholar
• Cannon R, Ruha AM, Kashani J. Acute hypersensitivity reactions associated with administration of crotalidae polyvalent immune Fab antivenom. Ann Emerg Med 2008; 51:407–411.
   PubMed Web of Science ®Google Scholar
• Tanen D, Ruha AM, Graeme K, Curry S. Epidemiology and hospital course of rattlesnake envenomations cared for at a tertiary referral center in Central Arizona. Acad Emerg Med 2001; 8:177–182.
   PubMed Web of Science ®Google Scholar
• Sherman A Minton, personal communication, Feb 1983.
   Google Scholar
• Smith DC, Reddi KR, Laing G, Theakston RGD, Landon J. An affinity purified ovine antivenom for the treatment of Viper berus envenoming. Toxicon 1992; 30:865–871.
   PubMed Web of Science ®Google Scholar
• Karlson-Stiber C, Persson H, Heath A, Smith D, Al-Abdulla IH, Sjöström L. First clinical experiences with specific sheep Fab fragments in snake bite. Report of a multicentre study of Vipera berus envenoming . J Intern Med 1997; 241:53–58.
   PubMed Web of Science ®Google Scholar
• Clark RF, McKinney PE, Chase PB, Walter FG. Immediate and delayed allergic reactions to Crotalidae polyvalent immune Fab (ovine) antivenom. Ann Emerg Med 2002; 39:671–676.
   PubMed Web of Science ®Google Scholar
• Dart RC, Seifert SA, Boyer LV, Clark RF, Hall E, McKinney P, et al. A randomized multicentre trial of crotaline polyvalent immune Fab (ovine) antivenom for the treatment for crotaline snakebite in the United States. Arch Intern Med 2001; 161:2030–2036.
   PubMed Web of Science ®Google Scholar
• Lavonas EJ, Kokko J, Schaeffer TH, Mlynarchek SL, Bogdan GM, Dart RC. Short-term outcomes after Fab antivenom therapy for severe crotaline snakebite. Ann Emerg Med 2011; 57:128–137.e3.
   PubMed Web of Science ®Google Scholar
• Seifert SA, Boyer LV. Recurrence phenomena after immunoglobulin therapy for snake envenomations: Part 1. Pharmacokinetics and pharmacodynamics of immunoglobulin antivenoms and related antibodies. Ann Emer Med 2001; 37:189–195.
   PubMed Web of Science ®Google Scholar
• Gutiérrez JM, León G, Lomonte B. Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation. Clin Pharmacokinet 2003; 42:721–741.
   PubMed Web of Science ®Google Scholar
• Dart RC, McNally J. Efficacy, safety, and use of snake antivenoms in the United States. Ann Emer Med 2001; 37:181–188.
   PubMed Web of Science ®Google Scholar
• Karlson-Stiber C, Salmonson H, Persson H. A nationwide study of Vipera berus bites during one year-epidemiology and morbidity of 231 cases. Clin Toxicol (Phila) 2006; 44:25–30.
   PubMed Web of Science ®Google Scholar
• Casewell NR, Al-Abdullah I, Smith D, Coxon R, Landon J.Immunological cross-reactivity and neutralisation of European viper venoms with the monospecific Vipera berus antivenom ViperaTAb. Toxins (Basel) 2014; 6:2471–2482.
   PubMed Web of Science ®Google Scholar
• Boyer LV, Seifert SA, Clark RF, McNally JT, Williams SR, Nordt SP, Walter FG, Dart RC. Recurrent and persistent coagulopathy following pit viper envenomation. Arch Intern Med 1999; 159:706–710.
   PubMed Web of Science ®Google Scholar
• Ruha AM, Curry SC, Albrecht C, Riley B, Pizon A. Late hematologic toxicity following treatment of rattlesnake envenomation with crotalidae polyvalent immune Fab antivenom. Toxicon 2011; 57:53–59.
   PubMed Web of Science ®Google Scholar
• Seifert SA, Kirschner R, Martin N. Recurrent, persistent, or late, new-onset hematologic abnormalities in Crotaline snakebite. Clin Toxicol (Phila) 2011; 49:324–329.
   PubMed Web of Science ®Google Scholar
• Lavonas EJ, Khatri V, Daugherty C, Bucher-Bartelson B, King T, Dart RC. Medically significant late bleeding after treated crotaline envenomation: a systematic review. Ann Emerg Med 2014; 63:71–78.e1.
   PubMed Web of Science ®Google Scholar
• Kitchens CS, Eskin TA. Fatality in a case of envenomation by Crotalus adamanteus initially successfully treated with polyvalent ovine antivenom followed by recurrence of defibrinogenation syndrome. J Med Toxicol 2008; 4:180–183.
   PubMedGoogle Scholar
• Ruha AM, Curry SC, Beuhler M, Katz K, Brooks DE, Graeme KA, et al.Initial postmarketing experience with crotalidae polyvalent immune Fab for treatment of rattlesnake envenomation. Ann Emer Med 2002; 39:609–615.
   PubMed Web of Science ®Google Scholar
• Seifert SA, Cano DN. Late, new-onset thrombocytopenia in a rattlesnake envenomation treated with a Fab antivenom. Clin Toxicol (Phila) 2013; 51:911–912.
   PubMed Web of Science ®Google Scholar
• Bush SP, Seifeert SA, Oakes J, Smith SD, Phan TH, Pearl SR, Reibling ET. Continuous IV Crotalidae Polyvalent Immune Fab (Ovine) (FabAV) for selected North American rattlesnake bit patients. Toxicon 2013; 69:29–37.
   PubMed Web of Science ®Google Scholar
• Ebell MH, Siwek J, Weiss BD, Woolf SH, Susman J, Ewigman B, Bowman M. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. Am Fam Physician 2004; 69:548–556.
   PubMed Web of Science ®Google Scholar
• “BTG settles Crofab® patent litigation with Bioclon and RDT”. The Pharmaletter. (10/10/2014; accessed 10/12/2014). http://www.thepharmaletter.com/article/btg-settles-crofab-patent-litigation-with-bioclon-and-rdt.
   Google Scholar